Clinical trials: CIN 2
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.
- Trial name
- FUTURE II (NCT00092534)
- Testing
- Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 12,167 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV
Pilots of Self-Collection for HPV DNA Detection
This study will evaluate a method of testing for human papillomavirus (HPV) DNA. For women who have had Pap test results that are abnormal, a new test can be done for HPV, that is, viruses that sometimes cause bumpy or flat…
- Trial name
- NCT00342511
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS)
Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer
This study compares how effective is the molecular screening (a blood test) using Pap smear as reference, that is, a comparison of these tests abilities to detect precursor lesions and cervical cancer among women of an open…
- Conditions
- I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS), III) Cervical Intraepithelial Neoplasia (CIN), CIN-1, CIN-2, CIN-3, IV) Low-grade Squamous Intraepithelial Lesion (LSIL)
- Trial name
- NCT07480902
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Human Papilloma Virus, Cervical Cancer
The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples
Cervical cancer is primarily caused by Human Papillomaviruses (HPV). Testing for HPV in cervical samples is now an option for cervical cancer screening.
- Conditions
- Human Papilloma Virus, Cervical Cancer, CIN 2/3
- Trial name
- SELFIE (NCT04423679)
- Testing
- Evalyn Brush
- Where
- United States
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- George Washington University
Cervical Cancers, Vulvar Cancer
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT03676101
- Testing
- 9-valent HPV Recombinant Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia Grade 2, DNA Methylation
The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)
High-risk precancerous cervical lesions are divided into stage 2 and 3 cervical intraepithelial neoplasia (CIN 2 and 3). CIN 3 represents a direct pre-stage of invasive cancer, has a high rate of progression and a high degree of…
- Trial name
- NCT05624827
- Testing
- Testing DNA methylation test for predicting prognosis of untreated CIN 2
- Where
- Slovenia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Maribor
Human Papilloma Virus Infection, Cervical Intraepithelial Neoplasia Grade 2/3
The HPV Self-test as a Test of Cure in Madagascar
The purpose of this study is to find out whether Self-HPV may be an accurate method for the follow-up of women with a history of HPV infection.
- Trial name
- NCT02811367
- Testing
- HPV test
- Where
- Madagascar
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Human Papillomavirus, CIN 2
Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women
The natural history of human papillomavirus (HPV) is most likely influenced by both innate and adaptive mucosal immunity. More specifically, we hypothesize that Toll like receptors (TLR) play an important role in cervical innate…
- Conditions
- Human Papillomavirus, CIN 2, CIN 3
- Trial name
- NCT01366742
- Where
- 2 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Cervical Intraepithelial Neoplasia Grade 2/3
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection
The FRDTM is easy to perform and does not require sophisticated laboratory technology and/or experienced pathologists for test result interpretation.
- Trial name
- NCT03366493
- Testing
- FRD, Cytology, HPV testing
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GY Highland Biotech LLC
Human Papilloma Virus, Dysplasia
Phase II Evaluation of AHCC for the Eradication of HPV Infections
This is a phase II randomized, double-blind placebo-controlled, crossover trial. The primary outcome of this trial is achieving durable eradication persistent high risk HPV infection determined by HPV negative test results…
- Conditions
- Human Papilloma Virus, Dysplasia, CIN1, CIN2
- Trial name
- AHCC4HPV (NCT02405533)
- Testing
- AHCC 3 grams once a day
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+…
- Conditions
- Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
- Trial name
- NCT04131413
- Testing
- pNGVL4aCRTE6E7L2
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
Digital Telecytology for Triage of HPV-Positive Women in Cameroon
This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon.
- Conditions
- Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Cancer Screening Methods
- Trial name
- NCT07550010
- Testing
- HPV testing (self-sampling), Digital telecytology, AI-assisted telecytology
- Where
- 2 sites in Cameroon
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Atypical Squamous Cell of Undetermined Significance, Cervical Carcinoma
Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening
This randomized clinical trial studies home-based HPV or clinic-based Pap screening for cervical cancer. It is not yet known whether home-based screening is more effective, cost-effective, and/or acceptable than clinic-based…
- Conditions
- Atypical Squamous Cell of Undetermined Significance, Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Health Status Unknown
- Trial name
- NCT01550783
- Testing
- Cervical Papanicolaou Test, Cytology Specimen Collection Procedure, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 1,335 people, healthy volunteers welcome
- Sponsor
- University of Washington
Cervical Intraepithelial Neoplasia
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
The main purpose of this study was to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.
- Trial name
- NCT05496231
- Testing
- HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation
- Where
- 68 sites in United States, Bulgaria and 6 more
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
This study is to demonstrate that the administration of the investigational vaccine can reduce the Combined Incidence of HPV types 6/11/16/18/31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3)…
- Trial name
- NCT05668572
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
- Where
- 3 sites in China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Atypical Squamous Cell of Undetermined Significance, ASC-US
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
This study compares the efficacy of cytology (Pap smear) with the molecular screening in their ability to detect reactive cellular changes in the cervix among an open population
- Conditions
- Atypical Squamous Cell of Undetermined Significance, ASC-US, Atypical Glandular Cells of Uncertain Significance, AGUS
- Trial name
- NCT07211204
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Lesion
Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions
The goal of this observational study is to compare the accuracy and sensitivity of High-throughput human papilloma virus(HPV) typing and integrated assays with routine screening protocols (Cobas HPV test combined with thinprep…
- Trial name
- NCT05851079
- Testing
- TCT test, Vaginoscopy, High throughput HPV typing and integration detection methods
- Where
- China
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Cervical Cancer, Vulvar Cancer
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04425291
- Testing
- 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Human Papillomavirus Infection, Cervical Cancer
Clinical Evaluation of Detection of High Risk HPV in Urine
Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer.
- Conditions
- Human Papillomavirus Infection, Cervical Cancer, Human Papilloma Virus, Negative for Intraepithelial Lesion or Malignancy
- Trial name
- Urine-hrHPV (NCT05210348)
- Where
- 3 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital